Research programme: epigenetic modulators - Oryzon

Drug Profile

Research programme: epigenetic modulators - Oryzon

Alternative Names: LSD1 inhibitors - Oryzon; ORY 3001

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oryzon
  • Class Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Unspecified
  • Research Autoimmune disorders; Cancer; Inflammation
  • No development reported Viral infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Viral-infections in Spain (PO)
  • 28 Jul 2017 Oryzon Genomics intends to file an IND/CTA in 2017
  • 09 May 2017 Preclinical trials in Undefined indication in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top